CRISPR Therapeutics (NASDAQ: CRSP) reported Q2 EPS of ($0.94), $0.26 better than the analyst estimate of ($1.20). Revenue for the quarter came in at $10.18 million versus the consensus estimate of $7.46 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.